We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Chilblain Lupus Erythematosus Hutchinson: Successful Treatment With Mycophenolate Mofetil

Ingrid Boehm, MD; Thomas Bieber, MD, PhD
Arch Dermatol. 2001;137(2):235-236. doi:.
Text Size: A A A
Published online


Chilblain lupus erythematosus (CHLE) is a rare, acrolocalized lupus erythematosus (LE) subset characterized by erythematous skin lesions resembling frostbite. In contrast to other LE subsets, CHLE is refractory to conventional therapies.13 Here we present the first case of CHLE that responded to mycophenolate mofetil.

Doutre  MSBeylot  CBeylot  JPompougnac  ERoyer  P Chilblain lupus erythematosus: report of 15 cases. Dermatology. 1992;18426- 28
Link to Article[[XSLOpenURL/10.1159/000247494]]
Millard  LGRowell  NR Chilblain lupus erythematosus (Hutchinson). a clinical and laboratory study of 17 patients. Br J Dermatol. 1978;98497- 506
Link to Article[[XSLOpenURL/10.1111/bjd.1978.98.issue-5]]
Uter  WProksch  ESchauder  S Chilblain Lupus erythematodes. Hautarzt. 1988;39602- 605
Aoki  TIshizawa  THozumi  YAso  KKondo  S Chilblain lupus erythematosus of Hutchinson responding to surgical treatment: a report of two patients with anti-Ro/SSA antibodies. Br J Dermatol. 1996;134533- 537
Link to Article[[XSLOpenURL/10.1111/j.1365-2133.1996.tb16244.x]]
Pichlmayr  R European mycophenolate mofetil cooperative study group, placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;3451321- 1325
Link to Article[[XSLOpenURL/10.1016/S0140-6736(95)92534-1]]
Allison  ACEugui  EM Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant. 1993;796- 112
Blaheta  RALeckel  KWittig  B  et al.  Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl Immunol. 1998;6251- 259
Link to Article[[XSLOpenURL/10.1016/S0966-3274(98)80015-4]]
Goldblum  RMcHugh  DSchiff  M  et al.  2-Morpholino-ethyl mycophenolic acid (ME-MPA) inhibits lymphocyte mitogen responses in rheumatoid arthritis [abstract]. Clin Pharmacol Ther. 1990;7193
Dooley  MACosio  FGNachman  PH  et al.  Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol. 1999;10833- 839
Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure 1.

Chilblain lupus erythematosus on the fingers of a 75-year-old woman.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Improvement of chilblain lupus erythematosus after 14 weeks of mycophenolate mofetil treatment.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

27 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections